Spinal muscular atrophy (SMA) is one of the leading genetic diseases of children and infants. SMA is caused by deletions or mutations of Survival Motor Neuron 1 ( SMN1 ) gene. SMN2 , a nearly identical copy of SMN1 , cannot compensate for the loss of SMN1 due to predominant skipping of exon 7. While various regulatory elements that modulate SMN2 exon 7 splicing have been proposed, intronic splicing silencer N1 (ISS-N1) has emerged as the most promising target thus far for antisense oligonucleotide-mediated splicing correction in SMA. Upon procuring exclusive license from the University of Massachussets Medical School in 2010, Ionis Pharmaceuticals (formerly ISIS Pharamaceuticals) began clinical development of Spinraza ™ (synonyms: Nusinersen, IONIS-SMN RX , ISIS-SMN RX ), an antisense drug based on ISS-N1 target. Spinraza ™ showed very promising results at all steps of the clinical development and was approved by US Food and Drug Administration (FDA) on December 23, 2016. Spinraza ™ is the first FDA-approved treatment for SMA and the first antisense drug to restore expression of a fully functional protein via splicing correction. The success of Spinraza ™ underscores the potential of intronic sequences as promising therapeutic targets and sets the stage for further improvement of antisense drugs based on advanced oligonucleotide chemistries and delivery protocols.
Contents
- Regular Articles
-
January 26, 2017
- Regular Articles
- Regular Articles
-
Open AccessThymoquinone attenuates brain injury via an antioxidative pathway in a status epilepticus rat modelMarch 25, 2017
- Regular Articles
- Regular Articles
-
April 30, 2017
- Regular Articles
-
April 30, 2017
- Regular Articles
-
May 11, 2017
- Regular Articles
- Regular Articles
-
May 31, 2017
- Regular Articles
- Regular Articles
- Regular Articles
-
August 12, 2017
- Regular Articles
-
September 14, 2017
- Regular Articles
-
September 12, 2017
- Regular Articles
-
Open AccessSolitaire stent in the treatment of acute ischemic stroke with large cerebral artery occlusionOctober 15, 2017
- Regular Articles
-
October 15, 2017
- Regular Articles
-
October 28, 2017
- Regular Articles
-
November 2, 2017
- Regular Articles
-
October 29, 2017
- Regular Articles
-
October 28, 2017
- Regular Articles
-
November 15, 2017
- Regular Articles
-
November 15, 2017
- Regular Articles
-
Open AccessOne-shot synesthesiaNovember 25, 2017
- Regular Articles
-
November 30, 2017
- Regular Articles
-
December 19, 2017
- Regular Articles
- Regular Articles
-
December 29, 2017
- Regular Articles
-
December 29, 2017
- Regular Articles
-
December 29, 2017